APA Citation

Trondl, R., Heffeter, P., Jakupec, M. A., Berger, W., & Keppler, B. K. (2012). NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer. BioMed Central.

Citação norma Chicago

Trondl, Robert, Petra Heffeter, Michael A. Jakupec, Walter Berger, and Bernhard K. Keppler. NKP-1339, a First-in-class Anticancer Drug Showing Mild Side Effects and Activity in Patients Suffering From Advanced Refractory Cancer. BioMed Central, 2012.

MLA Citation

Trondl, Robert, et al. NKP-1339, a First-in-class Anticancer Drug Showing Mild Side Effects and Activity in Patients Suffering From Advanced Refractory Cancer. BioMed Central, 2012.

Advarsel: Disse citationer er muligvist ikke 100% nøjagtige.